Novo-Nordisk - Insulinpräparate

Das Geschäft mit Insulinpräparaten ist von der Wirtschafts- und Finanzkrise kaum betroffen.

Aktuell sind weltweit 250 Mio. Menschen an Diabetes erkrankt.

Mit Blick auf die Lebensweise in den Industrieländern dürfte deren Zahl künftig noch zunehmen. Für die Dänen heißt dies: Das Wachstum ist gut planbar  Hoepage: http://www.novonordisk.com/

 

Key facts

• A world lead within diabetes and haemostasis management
• Sales totalled DKK 45.6 billion in 2008 (Eur 6.1 billion)
• In 2008 total insulin market of 52% and modern insulin market share 44%, measured by volume (Source IMS)
• Some 26,500 Full time employees
• Focus on core areas with large unmet medical needs: Diabetes care, haemostasis, growth hormone disorders and other biopharmaceuticals
• Strong global marketing network
• Listed on NASDAQ OMX Copenhagen, London and New York Exchanges

 

 

 

Der jüngste Kurssprung bei Novo Nordisk könnte sich als Big Point entpuppen. Seit Jahresbeginn bahnt sich die Aktie einen Weg durch die Kursregion um 46,20 Euro. Zwischen Dezember 2007 und April 2008 wurde sie dort viermal ausgebremst und stürzte anschließend mehr als 30 Prozent in die Tiefe.

Die Chancen, dass der technische Ausbruch nicht nur ein Intermezzo ist, stehen gut. Denn der im August gestartete Aufwärtstrend wirkt gefestigt: Im Bereich Autoimmunerkrankungen wurde kürzlich eine Forschungskooperation begründet, im Hauptgeschäftsfeld Diabetes startete eine Phase-1-Studie für ein orales Insulin, und für das humane GLP-1-Analogon Liraglutide (Victoza®) erwartet der dänische Healthcare-Konzern "innerhalb von Wochen" Feedback von der FDA.

Die Aktie ist mit einem Kurs-Gewinn-Verhältnis von 17 (auf Basis von 2010) zwar kein Schnäppchen mehr, doch überzeugen das solide Wachstum bei Erlösen und Gewinnen sowie die hohen Nettogewinnmargen von zuletzt 22,2 Prozent.

Quelle: http://www.aerztezeitung.de/praxis_wirtschaft/...ie-kaempft-frei.html   vom 18.01.2010  

 

Wir sind ein international tätiges Pharmaunternehmen mit Hauptsitz in Dänemark und Tochtergesellschaften in 79 Ländern weltweit und ca. 26.000 Mitarbeitern. In unseren Kernbereichen, der Herstellung und dem Vertrieb von Hormonen wie Insulin, Wachstumshormon, Oestrogen-/ Gestagen-Präparaten sowie Gerinnungsfaktoren, basiert unser Erfolg auf intensiven Forschungs- und Entwicklungsaktivitäten und ist durch Spitzenpositionen auf den internationalen Märkten gekennzeichnet. Unser Name steht für hohe fachliche und persönliche Qualifikation in allen Unternehmensbereichen sowie hohe Produktqualität und Kundennähe.

www.novonordisk.de  

JPMorgan hat Novo Nordisk nach der Zulassung von Liraglutide bei Diabetes-II-Patienten in Japan auf "Neutral" belassen. Wenngleich die Marktstimmung von der Nachricht profitieren dürfte, seien Rückschlüsse auf den Zulassungsprozess in den USA seien nur begrenzt möglich, schrieb Analyst Richard Vosser in einer am Donnerstag vorgelegten Studie. Eine Zulassung in den USA sei alles andere als sicher.

AFA0017 2010-01-21/10:59


© 2010 APA-dpa-AFX-Analyser  

News
EU OKs Warburg Pincus, Novo Nordisk To Buy Archimedes Pharma
PrintReprintsCommentRecommend (0)
Bookmark and Share
1-25-10 5:35 AM EST | E-mail Article

BRUSSELS -(Dow Jones)- The European Commission Monday cleared private equity firm Warburg Pincus and Denmark's Novo Nordisk Foundation to acquire control of Archimedes Pharma Ltd.
Archimedes Pharma is a U.K.-based pharmaceutical group focused on hospitals, with products for oncology, pain, neurology and critical care, the commission said.

-By Alessandro Torello, Dow Jones Newswires; +32 2 741 14 88; alessandro.torello@dowjones.com

 (END) Dow Jones Newswires
 01-25-100535ET
 Copyright (c) 2010 Dow Jones & Company, Inc.  

Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes

PRINCETON, N.J., Jan. 25 /PRNewswire/ -- Novo Nordisk , a global healthcare company, announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

Victoza was evaluated in The Liraglutide Effect and Action in Diabetes (LEAD) phase III trials, the most comprehensive clinical development program conducted to date by Novo Nordisk in type 2 diabetes. In clinical studies including use as monotherapy and in combination with standard diabetes treatments, Victoza produced significant reductions in A1C and also was associated with weight loss.

"Novo Nordisk is committed to developing safe and effective drugs to treat diabetes, which is why the FDA approval of Victoza represents such an important milestone for the company and for people with type 2 diabetes," says Alan C. Moses, M.D., vice president, and chief global medical officer of Novo Nordisk. "Victoza will be a substantial addition to our diabetes portfolio and we believe many people with type 2 diabetes will benefit from this treatment."

"Maintaining control of blood sugar remains a challenge for many type 2 diabetes patients and without control, patients are at risk of developing serious and life-threatening complications, " said Alan J. Garber, MD, PhD, FACE, Professor of Medicine, Biochemistry and Molecular Biology, and Cellular Biology Department of Medicine Baylor College of Medicine Houston, Texas. "The approval of Victoza provides patients a once daily treatment that not only lowers blood sugar, but unlike many other diabetes therapies, does not promote weight gain and is associated with weight loss in the majority of patients. Additionally, it offers patients an attractive new treatment option that has consistently performed well when compared to other currently available treatments."

The American Diabetes Association and European Association for the Study of Diabetes as well as the American Association of Clinical Endocrinologists and the American College of Endocrinology recently updated their treatment algorithms for type 2 diabetes. The algorithms recommend GLP-1 agonists like Victoza as a viable treatment option when blood sugar goals are not met or maintained with lifestyle adjustments and metformin.

Novo Nordisk expects to introduce Victoza in the U.S. market in 4 - 6 weeks. In addition to the U.S. approval, Victoza has been approved by the European Medicines Agency (EMEA) in all 27 European Union member states, Mexico and Iceland. On January 20th, Victoza was also approved in Japan. A New Drug Application was submitted for China in August 2009, regulatory decision is pending.

Indications and Usage

Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Victoza is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise. It has not been studied sufficiently in patients with a history of pancreatitis. Victoza should not be used to treat type 1 diabetes mellitus or diabetic ketoacidosis. It has not been studied in combination with insulin.

About Victoza

Victoza is the first and only human GLP-1 analog with 97% homology to natural GLP-1. Like natural GLP-1, Victoza works by stimulating the beta cells to release insulin only when blood glucose levels are high. Due to this glucose-dependent mechanism of action, Victoza is associated with a low rate of hypoglycemia. The mechanism of blood glucose lowering also involves a delay in gastric emptying.

In clinical studies submitted for FDA review, Victoza's® safety and efficacy were evaluated in five trials, one of 52-weeks duration and four of 26-weeks duration. These multinational trials evaluated Victoza in monotherapy as well as in combination with one or two oral anti-diabetic medications and showed better lowering of blood glucose than active comparators such as sulfonylureas and thiazolidinediones. A1C reductions for Victoza 1.8 mg, in combination or as monotherapy, ranged from 1.0% to 1.5% across the five clinical studies with baselines ranging from 8.2% to 8.6%. Victoza 1.8 mg + metformin reduced A1C by 1.0% and reduced weight by 6.2lbs. The most common adverse reactions reported in patients treated with Victoza are headache, nausea, diarrhea, and anti-liraglutide antibody formation. Immunogenicity-related events, including urticaria, were more common among Victoza-treated patients than among comparator-treated patients in clinical trials.

For full prescribing information, please go to Victoza.com or call 1-877-4VICTOZA (484-2869).

Conference call

On January 26, 2010 at 08:00 am CET, corresponding to 02:00 am EST, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com. Presentation material for the conference call will be made available approximately one hour before on the same page, and a replay of the conference call will be available approximately two hours after its conclusion.

Important Safety Information

Victoza causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be ruled out by clinical or nonclinical studies. Victoza is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Based on the findings in rodents, monitoring with serum calcitonin or thyroid ultrasound was performed during clinical trials, but this may have increased the number of unnecessary thyroid surgeries. It is unknown whether monitoring with serum calcitonin or thyroid ultrasound will mitigate human risk of thyroid C-cell tumors. Patients should be counseled regarding the risk and symptoms of thyroid tumors.

In clinical trials, there were more cases of pancreatitis among Victoza-treated patients than among comparator-treated patients. If pancreatitis is suspected, Victoza should be discontinued. Victoza should not be re-initiated if pancreatitis is confirmed. Use with caution in patients with a history of pancreatitis.

When Victoza is used with an insulin secretagogue (e.g. a sulfonylurea) serious hypoglycemia can occur. Consider lowering the dose of the insulin secretagogue to reduce the risk of hypoglycemia.

There have been no studies establishing conclusive evidence of macrovascular risk reduction with Victoza or any other antidiabetic drug.

The most common adverse reactions reported in patients treated with Victoza are headache, nausea, diarrhea, and anti-liraglutide antibody formation. Immunogenicity-related events, including urticaria, were more common among Victoza-treated patients than among comparator-treated patients in clinical trials.

Victoza has not been studied in type 2 diabetes patients below 18 years of age and is not recommended for use in pediatric patients.

Victoza should be used with caution in patients with renal impairment and in patients with hepatic impairment.

About Type 2 Diabetes

Approximately 220 million people worldwide have diabetes, the vast majority of which is type 2 which is caused by a combination of insulin resistance and inadequate and progressive dysfunction of the cells (beta cells) that produce and release insulin. In fact, studies show that 50% of beta-cell function is lost by the time of diagnosis. In the U.S. alone, approximately 24 million people have type 2 diabetes. Despite the availability of many treatments, close to 45% of people with type 2 diabetes are not achieving A1C goals. Lack of glycemic control puts patients at serious risk; for every 1% increase in A1C above 6%, the risk of death increases by 20%.

Further complicating the disease, 85% of people with type 2 diabetes are overweight or obese, and obesity increases insulin resistance, cardiovascular risk, and mortality. People with type 2 diabetes are at high risk of cardiovascular disease and have higher morbidity and mortality when cardiovascular events occur.

As the burden of type 2 diabetes continues to grow, innovation in developing drugs and improving health care delivery is needed if the epidemic and its consequences are expected to be stopped or reversed.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Novo Nordisk

CONTACT: Media: Elin K. Hansen, +45-4442-3450, ekh@novonordisk.com; or
Investors: Klaus Bulow Davidsen, +45-4442-3716, klda@novonordisk.com; or
Kasper Roseeuw Poulsen, +45-4442-4471, krop@novonordisk.com; Hans Rommer,
+1-609-919-7937; hrmm@novonordisk.com; or In North America: An Phan,
+1-609-558-0420, anph@novonordisk.com

Web Site: http://www.novonordisk.com/  

Novo Nordisk erhält FDA-Zulassung für Victoza
Kopenhagen (BoerseGo.de) - Der dänische Diabetesspezialist Novo Nordisk hat von der US-Gesundheitsbehörde FDA die Zulassung für das Medikament Victoza erhalten. Victoza sei zur Behandlung von Diabetes mellitus Typ 2 bei Erwachsenen zugelassen worden, teilte das Unternehmen am Dienstag mit. Victoza darf den Angaben zufolge sowohl zur Einzelanwendung als auch in Kombination mit anderen Medikamenten verschrieben werden. Die Markteinführung in den USA soll in den kommenden Wochen erfolgen. In Europa und Japan ist das Medikament ebenfalls bereits zugelassen.
(© BörseGo AG 2007 - http://www.boerse-go.de, Autor: Baron Oliver, Redakteur)


© 2010 BörseGo  

BAGSAERD, DENMARK--(Marketwire - February 2, 2010) -


Novo Nordisk increased operating profit by 21% in 2009

In 2010, operating profit is expected to increase by around 10%

-- Sales increased by 12% in Danish kroner and by 11% in local currencies.

      *Sales of modern insulins increased by 24%
      (23% in local currencies).

      *Sales of NovoSeven® increased by 11%
      (10% in local currencies).

      *Sales of Norditropin® increased by 14%
      (10% in local currencies).

      *Sales in North America increased by 21%
      (15% in local currencies).

      *Sales in International Operations increased by 17%
      (19% in local currencies).

-- Gross margin improved by 1.8 percentage points to 79.6% in 2009,
  primarily reflecting continued productivity improvements, price
  increases in the US and a positive currency impact of around 0.4
  percentage points.

-- Reported operating profit increased by 21% to DKK 14,933 million.
  Adjusted for the impact from currencies underlying operating profit
  increased by more than 15%.

-- Net profit increased by 12% to DKK 10,768 million. Earnings per share
  (diluted) increased by 15% to DKK 17.82.

-- At the Annual General Meeting on 24 March 2010, the Board of Directors
  will propose a 25% increase in dividend to DKK 7.50 per share of DKK 1.
  The Board of Directors has furthermore decided to initiate a new share
  repurchase programme of DKK 7.5 billion during 2010.

-- In January 2010, Novo Nordisk received marketing authorisation for
  Victoza®, the once-daily human GLP-1 analogue for the treatment of
  type 2 diabetes, from both the US Food and Drug Administration (FDA)
  and the Japanese Ministry of Health, Labour and Welfare.

-- For 2010, sales growth measured in local currencies is expected to be
  in the range of 6-10% whereas operating profit measured in local
  currencies is expected to increase by around 10%.

Lars Rebien Sørensen, president and CEO, said: "We are satisfied with the solid business performance in 2009, which is primarily driven by the robust sales growth for our portfolio of modern insulins. The launch of Victoza® in Europe is very encouraging and we look forward to continuing the global roll-out of Victoza® following the recent approvals in the US and Japan."

Further information about Novo Nordisk is available on the company's homepage http://novonordisk.com/

Company Announcement no 4 2010 : http://hugin.info/2013/R/1379438/339497.pdf  

Kopenhagen (BoerseGo.de) - Der dänische Diabetesspezialist Novo Nordisk ist im Geschäftsjahr 2009 profitabel gewachsen. Die Umsatzerlöse erhöhten sich gegenüber dem Vorjahr um 12 Prozent von 45,55 Millionen DKK auf 51,08 Millionen DKK, wie das Unternehmen am Dienstag mitteilte. Das operative Ergebnis konnte um 21 Prozent von 12,37 Millionen DKK auf 14,93 Millionen DKK zulegen. Unter dem Strich wuchs das Nettoergebnis um 12 Prozent von 9,65 Millionen DKK auf 10,77 Millionen DKK.

Der Vorstand wird der Hauptversammlung am 24. März 2010 die Anhebung der Dividende um 25 Prozent auf 7,50 DKK pro Aktie vorschlagen. Zudem kündigte das Unternehmen ein neues Aktienrückkaufprogramm für 2010 im Volumen von 7,5 Milliarden DKK an.

Für das laufende Jahr rechnet das Unternehmen mit einem Umsatzanstieg um 6 bis 10 Prozent und einem Anstieg des operativen Gewinns um 10 Prozent, jeweils gemessen in lokalen Währungen.
(© BörseGo AG 2007 - http://www.boerse-go.de, Autor: Baron Oliver, Redakteur)


© 2010 BörseGo  

Die Citigroup hat das Kursziel für Novo Nordisk nach Zahlen von 330,00 auf 360,00 dänische Kronen angehoben, die Einstufung aber auf "Hold" belassen. Insgesamt habe der Pharmakonzern die Markterwartungen erfüllt, schrieb Analyst Mark Dainty in einer Studie vom Mittwoch. Dainty passte seine Prognosen an die gestiegenen Unternehmensprognosen für 2010 an. Der Konzern biete zwar noch immer ein hohes Wachstum, doch spiegele sich dies zunehmend in der Bewertung wider.

AFA0024 2010-02-03/11:13


© 2010 APA-dpa-AFX-Analyser  

http://www.ariva.de/chart/images/...a100562464~b16~L1~VCandleStick~W1
Der Jahres-Chart von Novo-Nordisk (L&S RT) sieht als als Mountain gut aus, und ich habe heute 100 zu 50 gekauft.
Als Candlestik (L&S RT) wirkt er extrem flach, weil da 4 Dochte bis über 300 € ragen. Wie kommt das denn?
Wenn es wirklich Dummis gibt, die in einem engen Markt "billigst" ordern und dann so einen Preis zahlen,
dann kann ich doch gleich mal eine Verkaufsorder über 200 € erteilen und geduldig auf´s nächste Dummi warten.
Oder sind solche Charts fehlerhaft? -  Wenn niemand antwortet muß ich wohl bei Lange und Schwarz anfragen.
Oder vielleicht antwortet freundlicherweise ein börsenerfahrener Moderator?  

Vermute mal, dass es sich um einen fehlerhaften Chart handelt.
Wäre ja zu einfach.
Würde mich schon interessieren was L&S dazu sagt, oder ist es evtl nur ein Arivafehler.  

Transaction in Own Shares






Novo Nordisk A/S - Share repurchase programme

On 2 February 2010 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to
DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.


Since the announcement as of 8 February 2010, the following transactions have
been made under the programme:

                       Number of shares Average purchase        Transaction
                                              price       value,
                                                                    DKK

Accumulated, last               435,000                            162,272,753
announcement

08 February 2010                 90,000          373.8999           33,650,991

09 February 2010                 90,000          374.0000           33,660,000

10 February 2010                 90,000          374.0290           33,662,610

11 February 2010                 90,000          378.7490           34,087,410

12 February 2010                 90,000          385.0110           34,650,990

Accumulated under the           885,000                            331,984,754
programme


Transactions related to Novo Nordisk's incentive programmes have resulted in a
net sale by Novo Nordisk of 359,222 B shares in the period from 8 February 2010
to 12 February 2010. The shares in these transactions were not part of the Safe
Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 31,281,948
treasury shares, corresponding to 5.0% of the share capital. The total amount of
shares in the company is 620,000,000 including treasury shares.


Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.

Further information:


Media:                                  Investors:


Elin K Hansen                           Klaus Bülow Davidsen

Tel: (+45) 4442 3450                    Tel: (+45) 4442 3176

ekh@novonordisk.com                     klda@novonordisk.com
           


                                        Kasper Roseeuw Poulsen

                                        Tel: (+45) 4442 4471

                                        krop@novonordisk.com
                                       


In North America:                       In North America:

Sean Clements                           Hans Rommer

Tel: (+1) 609 514 8316                  Tel: (+1) 609 919 7937

secl@novonordisk.com                    hrmm@novonordisk.com
           


Company Announcement no 9 / 2010




[HUG#1384418]





   Company Announcement no 9 2010:

http://hugin.info/2013/R/1384418/343190.pdf  

NOV@FWB (Novo Nordisk A-S) announced a cash dividend with ex-dividend date of 20100325. The declared cash rate is EUR 1.0074.

ISIN : DK0060102614  

Cheuvreux hat die Einstufung für die Aktien von Novo Nordisk auf "Underperform" und das Kursziel auf 381,00 dänischen Kronen belassen. Die Konkurrenten Amylin und Ely Lilly hätten Fortschritte bei der US-Zulassung eines Diabetes-Mittels gemacht, schrieb Analyst Laurent Flamme in einer Studie am Dienstag. Er rechne mit der Markteinführung im zweiten Halbjahr 2010 oder Anfang 2011.

AFA0046 2010-03-16/13:03


© 2010 APA-dpa-AFX-Analyser  

Die Credit Suisse hat das Kursziel für Novo Nordisk vor Quartalszahlen von 380,00 auf 470,00 dänische Kronen angehoben und die Einstufung auf "Outperform" belassen. Auf Basis lokaler Währungen dürfte der Umsatz in den ersten drei Monaten um acht und der Gewinn je Aktie um 14 Prozent gestiegen sein, schrieb Analystin Luisa Hector in einer Studie vom Freitag. Die Diabetes-Sparte dürfte erneut solide Ergebnisse vorlegen. Nach zuletzt guter Kursentwicklung sollte nun eine Phase der Konsolidierung folgen. Dennoch blieben die Papiere des dänischen Pharmakonzerns eines der defensivsten Investments im europäischen Sektor.

AFA0051 2010-04-23/12:42


© 2010 APA-dpa-AFX-Analyser  

 

Die Berenberg Bank hat die Einstufung für Novo Nordisk nach Zahlen auf "Hold" und das Kursziel auf 366,00 dänischen Kronen belassen. Die Erstquartalszahlen des Pharmaherstellers seien besser als von ihm erwartet ausgefallen, schrieb Analyst Alistair Campbell in einer Studie vom Dienstag. Einmaleffekte hätten die Ergebnisse aber begünstigt.

AFA0087 2010-04-27/16:30  

COPENHAGEN —

Danish drug maker Novo Nordisk A/S said Tuesday its first quarter profit soared 23 percent, helped by increased sales of its core insulin products.

The world's top producer of insulin said net profit in the January to March period reached 3.3 billion kroner ($595 million), up from 2.7 billion kroner in the same period in 2009.

Sales increased by 9 percent to 13.7 billion kroner ($2.45 billion) from 12.5 billion kroner.

"We are encouraged by the solid business performance in the first quarter of 2010. The increasing use of our modern insulins is the primary driver of growth," Chief Executive Lars Rebien Soerensen said.

Rebien Soerensen added the launch of new diabetes drug Victoza in Europe was "progressing well" in the United States and Europe.

License fees and other operating income were 224 million kroner ($40.15 million), up from 87 million kroner in the first three months of 2009. The development is primarily driven by income from Novo Nordisk's portfolio of intellectual property including a non-recurring income of approximately 100 million kroner related to a settlement, the group said.

Novo Nordisk upgraded its forecast for operating profit growth in 2010 to "more than 10 percent," from an earlier forecast of "around 10 percent."

The company's shares rose 2.10 percent to 455 kroner ($81.55) in morning trading in Copenhagen.

Headquartered in Copenhagen, Novo Nordisk employs 29,000 people in 76 countries.

---

On the net:

http://www.novonordisk.com  

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Novo Nordisk Inc., a global healthcare company and leader in diabetes care, has been recognized as the "Best Place to Work in New Jersey" by NJBiz, the state's largest weekly business newspaper. This is the fourth time in six years the company has achieved this honor. Earlier this year, the company was recognized for the second consecutive year as one of FORTUNE's "100 Best Companies to Work For."

(Logo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO )

"It is an honor for Novo Nordisk to be named the #1 Best Place to Work in New Jersey four of the last six years," said Jeff Frazier, vice president of human resources. "The sustained level of employee engagement that enables us to maintain such a high ranking is indicative of our employees' commitment to our triple bottom line, as well as the company's mission to change diabetes and help people living with the diseases we treat."

The ranking is based on an independent assessment of policies, practices and demographics as well as a comprehensive employee survey.

In the survey, employees expressed a high level of satisfaction with their work environment. Nearly all of those surveyed had positive responses to the statements, "I would recommend my company's products/services to a friend," "I am willing to give extra effort to help my company succeed," and "I can trust what this organization tells me."

Novo Nordisk's recognition can be attributed in part to unique programs like College Coach, which helps parents navigate how to finance their children's college education. A recently launched program called "I am Novo Nordisk" affirms employees' positive responses to such programs. In "I am Novo Nordisk," employees who exemplify the company's values share their stories about why they love working for the company.

The "Best Place to Work in New Jersey" award is part of the weekly publication's annual survey to honor the companies in New Jersey that show a dedication to their employees' growth and quality of life, which was published in a supplement to the April 26 issue and online at http://www.njbiz.com/.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com

Novo Nordisk Inc.

CONTACT: Sean Clements of Novo Nordisk Inc., +1-609-514-8400 begin_of_the_skype_highlighting              +1-609-514-8400      end_of_the_skype_highlighting begin_of_the_skype_highlighting              +1-609-514-8400      end_of_the_skype_highlighting,
secl@novonordisk.com

Web Site: http://novonordisk-us.com/  

Bin ja mal sehr gespannt wohin die Reise mit Novo Nordisk noch geht.  

 

 

ueberlege mir nen Einstieg.

 

cheers

 

Iso